We Use
Genomic Insight to
Personalize Medicine.
Circulating biomarkers point to hidden cardiomyopathies and arrhythmogenic disorders
Cloud Analytics Drive Discovery
Worldwide links to allied databases stream biomarkers matched to diagnoses
Versatility in Application
Providing in-house biomarker analysis and diagnostic services while cutting-edge alliances foster next-generation instrumentation
Data Science Acceleration
Combining systems biology with advanced machine learning to support medical diagnoses and predict patient outcomes
Patient-focused Personal Medicine Mission
Providing models to healthcare providers seeking a total system biology approach to the universal, non-invasive diagnosis of heart disease
Unprecedented Insight. Impeccable Reliability.
CardiOmix S.r.l. began operations in 2019 with the aim of developing medical diagnostic products built on the research findings of Carlo Pappone, Professor of Cardiology and Director and Department of Arrhythmology and Electrophysiology of the Universit Vita-Salute San Raffaele and IRCCS Policlinico San Donato, Luigi Anastasia, Professor of Biochemistry, at Universit Vita-Salute San Raffaele, and Enrico Petretto, Professor of Systems Genetics and Deputy Director of the Centre and for Computational Biology, Duke-National University of Singapore Medical School.
The collaborative work of these investigators has established convincing evidence that the genetic background (phenotype) of an individual serves as a main determinant of epicardial electrophysiological abnormalities. Carriers of certain particular mutations exhibit more pronounced aberrations together with a more aggressive presentation. Thus, the blood relatives of patient who has been diagnosed with a life-threatening arrhythmogenic cardiomyopathy or has suffered a sudden cardiac death face an increased risk of cardiac arrest. This added risk calls for the medical examination and screening of all family members genetically associated with an acute cardiac episode. Unfortunately, many cases of electrophysiological abnormalities do not manifest in non-invasive electrocardiographic diagnoses.
We Take Pride in Our Numbers
15
Years of experience
10K
Patients treated
10
Biomarkers discovered
426
Publications
2
Patents
Our Partners
Are you ready to sharpen your diagnostic perception?
Genomic information, in concert with epigenomic signs manifested in transcriptomic, proteomic and metabolomic biomarkers, will add significantly to the future effectiveness of clinical diagnosis and cardiological risk stratification.
We started Cardiomix with the aim of forming commercial alliances that will make biomarker diagnosis broadly available to persons at risk of sudden cardiac death in Italy and throughout the world.